title: Can we safely discontinue imatinib? Searching for new endpoints in CML: a standardized definition of "cure".
authors.forename: Massimo
authors.initials: M
authors.lastname: Breccia
authors.forename: Giuliana
authors.initials: G
authors.lastname: Alimena
mesh_terms: D000970:Antineoplastic Agents / Q000008:administration & dosage*; D001549:Benzamides; D002986:Clinical Trials as Topic; D004334:Drug Administration Schedule; D023381:Endpoint Determination; D006801:Humans; D000068877:Imatinib Mesylate; D015464:Leukemia, Myelogenous, Chronic, BCR-ABL Positive / Q000188:drug therapy* / Q000473:pathology; D019653:Myeloablative Agonists / Q000008:administration & dosage*; D010879:Piperazines / Q000008:administration & dosage*; D047428:Protein Kinase Inhibitors / Q000008:administration & dosage*; D011743:Pyrimidines / Q000008:administration & dosage*; D012008:Recurrence; D012074:Remission Induction; D012307:Risk Factors; D016896:Treatment Outcome
chemical_list: D000970:Antineoplastic Agents; D001549:Benzamides; D019653:Myeloablative Agonists; D010879:Piperazines; D047428:Protein Kinase Inhibitors; D011743:Pyrimidines; D000068877:Imatinib Mesylate